404 related articles for article (PubMed ID: 28118981)
21. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
22. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
23. MdmX inhibits Smad transactivation.
Kadakia M; Brown TL; McGorry MM; Berberich SJ
Oncogene; 2002 Dec; 21(57):8776-85. PubMed ID: 12483531
[TBL] [Abstract][Full Text] [Related]
24. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Grier JD; Xiong S; Elizondo-Fraire AC; Parant JM; Lozano G
Mol Cell Biol; 2006 Jan; 26(1):192-8. PubMed ID: 16354690
[TBL] [Abstract][Full Text] [Related]
25. MDMX: a novel p53-binding protein with some functional properties of MDM2.
Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
[TBL] [Abstract][Full Text] [Related]
27. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
29. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
30. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
[TBL] [Abstract][Full Text] [Related]
31. The p53 orchestra: Mdm2 and Mdmx set the tone.
Wade M; Wang YV; Wahl GM
Trends Cell Biol; 2010 May; 20(5):299-309. PubMed ID: 20172729
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry.
Zhu Y; Regunath K; Jacq X; Prives C
Genes Dev; 2013 Aug; 27(16):1739-51. PubMed ID: 23934659
[TBL] [Abstract][Full Text] [Related]
33. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
34. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
35. DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.
Li C; Chen L; Chen J
Mol Cell Biol; 2002 Nov; 22(21):7562-71. PubMed ID: 12370303
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
[TBL] [Abstract][Full Text] [Related]
37. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
38. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.
Venkatesh D; O'Brien NA; Zandkarimi F; Tong DR; Stokes ME; Dunn DE; Kengmana ES; Aron AT; Klein AM; Csuka JM; Moon SH; Conrad M; Chang CJ; Lo DC; D'Alessandro A; Prives C; Stockwell BR
Genes Dev; 2020 Apr; 34(7-8):526-543. PubMed ID: 32079652
[TBL] [Abstract][Full Text] [Related]
39. MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.
Marine JC; Jochemsen AG
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27371671
[TBL] [Abstract][Full Text] [Related]
40. Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.
Heltberg ML; Chen SH; Jiménez A; Jambhekar A; Jensen MH; Lahav G
Cell Syst; 2019 Dec; 9(6):548-558.e5. PubMed ID: 31812692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]